47
472145AF8
Jazz Pharmaceuticals Plc
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company making medicines for serious conditions in neuroscience and oncology, including Xyrem for narcolepsy and Epidiolex, used by patients around the world. It was founded in California in 2003 and later re-incorporated in Dublin, Ireland after a merger. The name comes from co-founder Bruce Cozadd's love of jazz: he saw the music's blend of free improvisation and shared structure as a perfect metaphor for inventing new drugs within strict regulation.
CONVERTIBLECUSIP: 472145AF8HealthcareIE1 derivative reporter
2.00% Convertible Senior Notes due 2026 issued by Jazz Investments I Ltd
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
